Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Thursday 16 January, 2020

JP Morgan Sec LLC

AbbVie Inc. 38.b AMENDMENT

RNS Number : 0529A
J.P. Morgan Securities LLC
16 January 2020
 

Ap27

 

 

AMENDMENT

FORM 38.5(b)

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNISED 

INTERMEDIARY STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

 

 

1.          KEY INFORMATION

 

Name of exempt principal trader

J.P Morgan Securities LLC

Company dealt in

AbbVie Inc.

Class of relevant security to which the dealings being disclosed relate (Note 1)

Common stock

Date of dealing

14 January 2020

 

2.          INTERESTS AND SHORT POSITIONS

 

(a)         Interests and short positions (following dealing) in the class of relevant security dealt in (Note 2)

 

 

Long

Short

 

Number

 

(%)

Number

 

(%)

(1) Relevant securities

 4,469,943                  0.30

(2) Derivatives (other than options)

 3,732,203                  0.25

 1,537,127                  0.10

(3) Options and agreements to purchase/sell

 947,300                  0.06

 621,500                  0.04

Total

  20,937,696  1.41

 6,628,570                  0.44

             

 

 

(b)         Interests and short positions in relevant securities of the company, other than the class dealt in (Note 2)

 

Class of relevant security:

Long

Short

 

Number

 

(%)

Number

 

(%)

(1) Relevant securities

 

(2) Derivatives (other than options)

 

 

(3) Options and agreements to purchase/sell

 

 

Total

 

 

             

 

Ap28

 

 

3.       DEALINGS (Note 3)

 

(a)      Purchases and sales

 

Purchase/sale

Number of relevant securities

Price per unit (USD) (Note 4)

Sale (Borrow Return)

 

Purchases

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales

138,800

 

100

1

1

1

1

1

2

9

1

1

2

1

102

3

1

16

1

1

300

1

3

1

2

1

72

7

5

2

2

10

162

2

1

101

930

2

500

935

3,073

500

938

200

13

19

357

12

2,085

1

1

17

2

1

198

47

11

1

1

500

17

1

3

1

1

102

2

2

1

2

2

302

102

100

2

2

2

1

1

2

7,029

23

1

1

1

1

 

200

100

100

67

100

24

161

400

3,073

19

2,085

300

500

200

100

100

100

100

24

2,305

1,522

23

NA

 

87.0900

 87.1000

 87.2000

 87.2200

 87.2700

 87.3100

 87.3550

 87.3567

 87.3700

 87.3800

 87.4000

 87.4100

 87.4200

 87.4300

 87.4600

 87.4669

 87.4800

 87.4900

 87.4967

 87.5200

 87.5300

 87.5400

 87.5500

 87.5700

 87.5800

 87.5971

 87.6000

 87.6100

 87.6200

 87.6260

 87.6400

 87.6600

 87.6800

 87.6900

 87.6970

 87.7000

 87.7200

 87.7288

 87.7327

 87.7340

 87.7365

 87.7400

 87.7469

 87.7689

 87.7751

 87.7875

 87.7899

 87.8000

 87.8200

 87.8276

 87.8300

 87.8400

 87.8429

 87.8449

 87.8591

 87.8900

 87.9000

 87.9040

 87.9065

 87.9400

 87.9500

 87.9600

 87.9700

 87.9800

 87.9900

 88.0200

 88.0300

 88.0400

 88.0600

 88.0700

 88.1000

 88.1100

 88.1200

 88.1300

 88.1500

 88.1600

 88.1700

 88.1800

 88.2000

 88.2026

 88.2200

 88.3000

 88.3800

 88.4300

 

 87.0900

 87.5100

 87.5200

 87.5300

 87.6000

 87.6200

 87.6400

 87.7125

 87.7327

 87.7500

 87.7899

 87.8133

 87.8400

 87.9550

 88.0100

 88.0200

 88.0800

 88.0900

 88.1700

 88.1996

 88.2000

 88.2026

 

 

(b)      Derivatives transactions (other than options transactions)

 

Product name,

e.g. CFD

Nature of transaction

(Note 5)

Number of relevant securities

(Note 6)

Price per unit

(Note 4)

Equity Swaps

Long

 

Short

100

 

3,073

2,085

23

87.0900 USD

 

87.7327 USD

87.7899 USD

88.2026 USD

 

 

(c)      Options transactions in respect of existing relevant securities

 

 

(i)       Writing, selling, purchasing or varying

 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 4)

 

 

 

 

 

 

 

 

 

(ii)      Exercising

 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 4)

 

 

 

 

 

(d)      Other dealings (including transactions in respect of new securities) (Note 3)

 

Nature of transaction

(Note 7)

Details

Price per unit

(if applicable) (Note 4)

 

 

 

 

Ap29

 

4.       OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities 
under any option referred to on this form or relating to the voting rights or future acquisition or 
disposal of any relevant securities to which any derivative 
referred to on this form is referenced. 
If none, this should be stated.

 

 

 

 

 

 

 

 

Is a Supplemental Form 38.5(b) attached? (Note 8)                    YES

 

 

Date of disclosure

16 January 2020

Contact name

Alwyn Basch

Telephone number

020 7742 7407

Name of offeree/offeror with which connected

Allergan plc

Nature of connection (Note 9)

Financial Advisor to Allergan plc

 

 

 

 

 

 

Ap31

 

 

SUPPLEMENTAL FORM 38.5(b)

 

 

 

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DETAILS OF OPEN POSITIONS

 

(This form should be attached to Form 38.5(b)) OPEN POSITIONS (Note 1)

 

Product name,

e.g. call option

Written or purchased

Number of relevant securities to which the option or derivative relates

Exercise price (Note 2)

Type, e.g. American, European etc.

Expiry date

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Written

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

Purchased

87,500

87,500

182,700

9,100

1,000

8,400

7,100

102,500

29,100

31,300

32,300

11,400

8,900

1,900

4,400

20,000

100,000

7,700

10,000

9,100

45,000

8,400

7,100

102,500

29,100

31,300

32,300

16,400

10,400

25,000

7,000

4,400

140,000

20,000

6,100

8,500

18,200

8,400

11,200

7,200

21,100

2,500

4,500

5,600

2,500

20,000

6,100

10,000

21,200

8,400

11,200

7,200

21,100

2,500

7,900

5,600

2,500

10,000

8,500

100,000

60.00

55.00

60.00

65.00

70.00

57.50

62.50

60.00

55.00

65.00

70.00

75.00

77.50

72.50

67.50

60.00

70.00

60.00

110.00

65.00

80.00

57.50

62.50

60.00

55.00

65.00

70.00

75.00

77.50

80.00

72.50

67.50

82.50

105.00

110.00

105.00

85.00

92.50

95.00

100.00

80.00

87.50

90.00

97.50

115.00

82.50

110.00

105.00

85.00

92.50

95.00

100.00

80.00

87.50

90.00

97.50

115.00

110.00

105.00

70.00

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

American

21FEB20

21FEB20

17JAN20

17JAN20

17JAN20

17JAN20

17JAN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

15JAN21

15JAN21

17JAN20

17JAN20

17JAN20

17JAN20

17JAN20

17JAN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

15JAN21

17JAN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

15JAN21

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

19JUN20

15JAN21

15JAN21

15JAN21

 

 

 

 

Notes

 

1.       Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.

 

2.       For all prices and other monetary amounts, the currency must be stated.

 

For full details of disclosure requirements, see Rules 8 and

38.5 of the Rules. If in doubt, consult the Panel.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISESFDFFMESSEFF

a d v e r t i s e m e n t